Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Icahn Is Forest’s Latest Wolf At The Door

Executive Summary

Specialty pharma Forest Pharmaceuticals Inc. has already spent months fending off doubts about the future of its pipeline as well as a potential federal ban prohibiting its long-time CEO from negotiating federal contracts. Now, the company has a new wolf at the door: dissident investor Carl Icahn.

You may also be interested in...

HHS Office of Inspector General Drops Challenge To Forest CEO Solomon

Amid drama from dissident investor Carl Icahn, Forest is relieved of the fear that the federal OIG could bar its CEO from contracting with government health care programs.

Still Needled By Icahn, Forest Nominates Three To Board

The specialty pharma countered the activist investor's June challenge with its own nominees, while defending its diversification strategy.

Investor Icahn Ups Offer For Clorox, But Bidding War “Unlikely”

The future of Burt’s Bees marketer Clorox is unclear with a buyout offer on the table from its largest shareholder.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts